Lutein and Zeaxanthin Supplementation in Preterm Very Low-Birth-Weight Neonates in Neonatal Intensive Care Units: A Multicenter Randomized Controlled Trial

Paolo Manzoni, MD1  Roberta Guardione, RN1  Paolo Bonetti, MD2  Claudio Priolo, MD1  Andrea Maestri, MD1  Caterina Mansoldo, MD2  Michael Mostert, MD3,5  Giovanni Anselmetti, MD4  Daniela Sardei, MD3,5  Massimo Bellettato, MD3,5  Paolo Biban, MD2  Daniele Farina, MD1

1 Neonatology and NICU, S. Anna Hospital, Torino, Italy  
2 Pediatrics/Neonatal Intensive Care Unit, Division of Pediatrics, Azienda Ospedaliera, Verona, Italy  
3 Division of Neonatology and Pediatrics, City Hospital, Thiene, Italy  
4 Referral Center for ROP of Piedmont, Torino, Italy  
5 Department of Pediatrics, University of Torino, Italy

Address for correspondence and reprint requests  Paolo Manzoni, MD, Neonatology and NICU, S. Anna Hospital, Azienda Ospedaliera, Regina Margherita, S. Anna, C. Spezia 60, 10126 Torino, Italy (e-mail: paolomanzoni@hotmail.com).

Abstract

Background  Human milk feeding protects against oxidative stress-induced damage in preterm neonates, including severe multifactorial diseases such as retinopathy of prematurity (ROP), necrotizing enterocolitis (NEC), and bronchopulmonary dysplasia (BPD). The carotenoids, which are not found in formula milk, might play a key role in these actions.

Methods  A multicenter, double-blind, randomized controlled trial was conducted in three tertiary Italian neonatal intensive care units. All preterm infants <32+6 weeks’ gestational age were eligible and were randomized to a single, oral, daily 0.5-mL dose of carotenoid supplementation (0.14 mg lutein + 0.0006 mg zeaxanthin) or placebo (5% glucose solution) from birth till 36 weeks’ corrected gestational age. Primary outcomes were threshold ROP, NEC > second stage, and BPD. Surveillance for detection of these diseases and for intolerance/adverse effects was performed.

Results  No treatment-related adverse effect was documented in the 229 analyzed infants, whose clinical/demographical characteristics were similar in the two groups. Threshold ROP incidence did not significantly differ in treated (6.2%) versus not treated infants (10.3%; p = 0.18). The same occurred for NEC (1.7% versus 5.1%; p = 0.15) and BPD (4.5% versus 10.3%; p = 0.07). Noteworthy, the progression rate from early ROP stages to threshold ROP was decreased by 50% (0.30 versus 0.44; p = 0.23).

Conclusion  Lutein/zeaxanthin supplementation in preterm infants is well tolerated. No significant effect was seen on threshold ROP, NEC, or BPD. The decreasing trends of these outcomes in the treatment group need to be assessed and confirmed on larger sample-sizes.
Progress in perinatal care has improved survival rates among preterm neonates. However, disability-free survival from preterm birth is increasingly hampered by several adverse, long-term outcomes of prematurity such as retinopathy of prematurity (ROP), necrotizing enterocolitis (NEC) and bronchopulmonary dysplasia (BPD).1

Prematurity itself plays the major role in such multifactorial late diseases. However, oxidative stress-induced damage related both to prematurity and to the type of care administered is speculated to play an important, additional role.2 As these preterm infants are susceptible to oxidative damage due to high metabolic rate and low levels of antioxidant enzymes, and this is a crucial step for the onset of many severe outcomes of prematurity, efforts have been addressed to the identification of protective strategies that will enhance their antioxidant functions.3

Maternal milk feeding is indicated for all premature infants as it provides valuable nutritional and immunologic benefits.4 Noteworthy, human milk is also protective towards some severe outcomes of prematurity such as sepsis,4 ROP,5 BPD, and NEC.6

The observation that fresh human milk is rich in many antioxidants7 (e.g., vitamin E, β-carotene, lutein, and lactoferrin) helps understand why human milk has is protective against many multifactorial diseases in which an oxidative stress-induced damage occurs (e.g., ROP, NEC, and BPD).

Among the antioxidant factors of human milk, the carotenoids (lutein, β-carotene, zeaxanthin, lycopene) are believed to play a crucial role.8 Carotenoids, a family of polyene lipophilic molecules, are not found in formulas. Colostrum contains a very high level of carotenoids, particularly of lutein (up to 140 µg/L) that is fivefold that of mature milk.9 Carotenoids provide protection against both light-induced and metabolic oxidative damage in the premature retina, and protection from oxidative stress in other developing tissues where oxidative insults occur.

As nutritional supplements, lutein and zeaxanthin were granted a generally recognized as safe (GRAS) status by the Food and Drug Administration in June 2004 (see GRAS Notice No. GNR 000140 issued by Center for Food Safety and Applied Nutrition/Office of Food Additive Safety10). On this ground, these two carotenoids are currently marketed worldwide, but only in some countries is lutein-supplemented formula milk available.

The present study assesses the outcomes of preterm infants given supplemented carotenoids (lutein and zeaxanthin) during their stay in the neonatal intensive care unit (NICU), as well as the safety and tolerability of these two supplements.

**Methods**

This study is a multicenter, prospective, randomized, double-blind, placebo-controlled trial conducted over a 12-month period in three NICUs of northern Italy.

All neonates with gestational age <32 weeks + 6 days (i.e., all those qualifying for screening of ROP) born within the study period, whether at one of the participant institutions or elsewhere, were eligible for the study. Parental refusal, admission after 48 hours of life, death prior to 72 hours of life, ophthalmologic disease already present at the time of randomization were exclusion criteria.

The primary objective of the study was to evaluate the effectiveness of the lutein + zeaxanthin supplementation, compared with placebo, in the prevention of threshold ROP, BPD, and necrotizing enterocolitis (NEC) of surgical stage (i.e., second or greater according to Bell’s classification11).

Secondary objectives were the assessment of the incidence of ROP of all stages, NEC of all stages; of intestinal perforation; of late-onset sepsis; of mortality prior to discharge; of severe (grade 3 to 4) intraventricular hemorrhage; of need for transfusions; of liver failure defined as 3 × elevation of normal serum liver enzymes values.

Surveillance for detection of all these outcomes, as well as for episodes of intolerance to the supplements or adverse effects, was performed till discharge or term corrected age, whichever came first. Measurements of serum liver enzymes values were performed at 4 weeks of age.

Infants were randomly allocated to one of two groups in a 1:1 ratio to receive carotenoids oral supplementation (group A) or placebo (group B). Randomization was stratified by center, and randomly permuted blocks of size 9 and 12 were used. The random allocation sequence was generated using ralloc.ado version 3.2.5 in Stata 9.2 (Stata-Corp, College Station, TX). The pharmacy at each center used these computer-generated randomization lists to form the two groups and prepared the drug doses in sealed opaque vials.

In detail, the study intervention consisted of daily oral administration of a mixture containing 0.14 mg of lutein and 0.0006 mg of zeaxanthin (equal to 0.5 mL of the product LuteinoOfla gtt, NEOOX Division of SOOFT Italia SpA, Montegiorgio, Italy) in group A infants, whereas group B infants received a daily oral administration of 0.5 mL of 5% glucose solution as placebo. Clinical and research staff remained unaware of study group assignments during the study.

As mentioned, the supplemented drug and placebo were administered in a single daily oral dose from birth till week 36 of gestational (corrected) age, starting from the first 48 hours of life.

Neonates not feeding in the first 48 hours received the drug/placebo by oral/nasogastric tube and were enrolled in the absence of gastric instability and/or repeated gastric residuals or emesis. If they repeatedly displayed gastric instability, gastric residuals, or vomit, they were enrolled at any point during the first week of life, depending on the first “efficacious” feedings. The day of life in which they first received the drugs or placebo was recorded in the database, and their statistics were limited to the days of administration/ exposure to the intervention.

Nutritional and feeding policies followed common protocols. Administration of fresh, expressed maternal milk was encouraged. Each mother could supply milk only for her infant. When needed, feeding was supplemented with a formula for very low-birth-weight (VLBW) infants (PreAptamil; Milupa Italia, Milano, Italy) not supplemented with lutein or zeaxanthin. Systematic surveillance of adverse events (e.g., vomiting, feeding intolerance, skin rashes) was
performed through daily infant examination until 2 days after end of treatment.

SOOFT Italia SpA supplied the lutein + zeaxanthin preparations, as well as the placebo in identical vials.

Definitions of Outcomes

NEC was defined as clinical signs with the presence of Pneumatos is intestinalis on abdominal X-rays, according to the Bell criteria.11

Severe RPD was defined as use of supplemental oxygen for 28 days plus 30% oxygen, positive pressure ventilation at 36 weeks’ postmenstrual age, or both.12

ROP was defined according to the Early Treatment for Retinopathy of prematurity study.13 Ophthalmologic screening for ROP was performed by one board-certified consultant ophthalmologist in each participating unit. Infants were first screened at 3 to 4 weeks of age and then at 1- to 2-week intervals, depending on the clinical picture and the severity of retinopathy at the discretion of the ophthalmologist and neonatologist. All infants were examined until regression of the ROP lesions, or until retinal vascularization was complete. In case of discharge prior to the week 36 of gestational age, infants with ongoing not threshold ROP lesions were considered still at risk of progression to more severe stages, and therefore the screening was not discontinued. The infants were revisited also after discharge by the same ophthalmologists in the hospital unit, at scheduled intervals, until either the development of ROP or the disappearance of the lesions. Gestational age was calculated using the expected date of delivery based on an ultrasound performed before 22 weeks’ gestation or—when ultrasound was not available—was determined by the attending neonatologist when the infant was admitted to the NICU based on neonatal clinical findings.

Neonates were all classified by their most severe ROP examination.

The screening ophthalmologists were unaware of treatment assignments or any other potential risk factors for ROP other than VLBW or gestational age ≥32 weeks. The decision to treat ROP was always taken according to the stage of the disease.

Late-onset sepsis was defined as occurring more than 72 hours after birth and before discharge. This condition was based on the detection of clinical signs and symptoms by the physician in charge, presence of laboratory findings consistent with sepsis, and isolation of a causative organism from blood (drawn from peripheral sites) or cerebrospinal or peritoneal fluid.14,15 Diagnostic criteria were based on the existing literature, guidelines from international consensus documents, and recommendations from the Italian Neonatology Society’s Fungal Infections Task Force.16,17

Presence and grade of intraventricular hemorrhage were documented by the most negative ultrasound finding available; intraventricular hemorrhage was classified by the Papile criteria.18

Categorical predictor variables were represented by percentages. Birth weight, gestational age, Apgar score, number of days receiving a given treatment, and daily amount of milk intake were represented by continuous variables. A complete list of the categorical and continuous variables considered is shown in►Table 1.

Proportions and continuous variables were compared using the Fisher exact two-tailed test and the t test, respectively. Risk ratios and 95% confidence intervals were calculated to compare cumulative between group incidences using Stata version 9.2.

The Wald test was used to assess the significance of the estimated coefficients. The likelihood ratio test was used to test the significance of the center-level variance component. Goodness-of-fit was evaluated through the log-likelihood of the fitted model. All tests were two-tailed, and p < 0.05 was considered statistically significant.

Sample size analysis predicted that 114 patients would be needed for each group, based on two-sided type I error rates of 0.05 or less and 80% power to detect a relative difference between treated and nontreated infants of at least 66% (decrease from 18 to 6%, given a pretrial incidence of 18%15) for threshold ROP.

A total of 638 and 376 infants in each group would have been needed to detect the same extent of significant differences between groups for BPD and NEC, given pretrial incidences of 3.6% and 6.0%, respectively. Given the low incidence of these last two outcomes in our pretrial data, the study was underpowered to detect possible significant differences.

Power calculations were performed according to S plus, Version 2000. Analysis of dichotomous outcomes and interpretation of results were performed as suggested in Cochrane Reviewers’ Handbook 4.2.2.19

SOOFT Italia SpA provided financial support with a grant but was not involved in the concept, design, enrollment, data collection, analysis and interpretation of its results, and decisions inherent the publication of the results.

Results

Of 247 VLBW infants considered for inclusion in the trial (►Fig. 1), 18 were not eligible either because they did not meet inclusion criteria (n = 1) or because the parents refused to participate (n = 14), or for other reasons (n = 3).

One infant in group A did not receive all the study doses, and four infants (two in group A and two in group B) had incomplete data, but all of them were included in the final analysis on an intent-to-treat basis.

The final analysis included 229 infants, 113 in group A and 116 in B. Clinical and demographic characteristics did not differ between the two groups (►Table 1).

Results of the study outcomes are reported in►Table 2.

Overall, threshold ROP incidence tended to be lower in the treated (6.2%) versus not treated (10.3%) infants (p = 0.18). The same occurred for BPD (4.5% versus 10.3%; p = 0.15) and NEC (1.7 versus 5.1%; p = 0.07). Of note, treatment was associated with a lower rate of progression from the early stages of ROP to the threshold stage (0.30 versus 0.44; p = 0.23).
No significant differences were seen also when clustering the analysis for type of infant feeding (human fresh milk versus formula milk).

Serum liver enzymes values at 4 weeks of age were normal and comparable in the two groups (►Table 3). Liver function evaluations did not disclose any hepatic adverse effect putatively attributable to the supplementation in any moments.

No adverse effects putatively attributable to the treatment was documented.

### Discussion
To our knowledge, this is the first randomized controlled trial (RCT) assessing the outcomes of preterm infants given a carotenoid supplementation since birth.

---

**Table 1** Demographics and Clinical Characteristics

<table>
<thead>
<tr>
<th></th>
<th>Group A: Lutein (n = 113)</th>
<th>Group B: Placebo (n = 116)</th>
<th>p Value Group A versus Group B</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Birth weight (g), mean ± SD (range)</td>
<td>1336 ± 417 (560–1485)</td>
<td>1271 ± 386 (600–1500)</td>
<td>0.29</td>
</tr>
<tr>
<td>Gestational age (wk), mean ± SD (range)</td>
<td>30.1 ± 1.8 (24–34)</td>
<td>29.7 ± 2.6 (25–34)</td>
<td>0.45</td>
</tr>
<tr>
<td>Sex (male/female)</td>
<td>44</td>
<td>56</td>
<td></td>
</tr>
<tr>
<td>Race (% of Caucasian)</td>
<td>85%</td>
<td>89%</td>
<td>0.90</td>
</tr>
<tr>
<td>Born at another facility (%)</td>
<td>16</td>
<td>21</td>
<td>0.39</td>
</tr>
<tr>
<td>Vaginal delivery (%)</td>
<td>22</td>
<td>29</td>
<td>0.40</td>
</tr>
<tr>
<td>Mother had preeclampsia (%)</td>
<td>21</td>
<td>26</td>
<td>0.55</td>
</tr>
<tr>
<td>Premature rupture of membranes</td>
<td>23</td>
<td>25</td>
<td>0.99</td>
</tr>
<tr>
<td>Use of antenatal corticosteroids</td>
<td>63</td>
<td>64</td>
<td>0.89</td>
</tr>
<tr>
<td>Use of antenatal antibiotics</td>
<td>70</td>
<td>73</td>
<td>0.99</td>
</tr>
<tr>
<td><strong>Clinical characteristics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean Apgar score at 5 min.</td>
<td>7.3</td>
<td>7.3</td>
<td>0.69</td>
</tr>
<tr>
<td>Use of surfactant (at least once)</td>
<td>61</td>
<td>68</td>
<td>0.26</td>
</tr>
<tr>
<td>Umbilical catheter positioned (d)</td>
<td>4.3</td>
<td>4.7</td>
<td>0.90</td>
</tr>
<tr>
<td>Intubation (d)</td>
<td>5.6</td>
<td>7.0</td>
<td>0.42</td>
</tr>
<tr>
<td>Mechanical ventilation (total d)</td>
<td>7.9</td>
<td>10.8</td>
<td>0.06</td>
</tr>
<tr>
<td>Supplemental oxygen (total d)</td>
<td>9.6</td>
<td>12.9</td>
<td>0.25</td>
</tr>
<tr>
<td>Incidence of early-onset neutropenia (%)</td>
<td>8.5</td>
<td>9</td>
<td>0.80</td>
</tr>
<tr>
<td>Use of TPN (d)</td>
<td>9.8</td>
<td>13.6</td>
<td>0.05</td>
</tr>
<tr>
<td>H2 blockers (total d)</td>
<td>5.3</td>
<td>6.4</td>
<td>0.40</td>
</tr>
<tr>
<td>Third-generation cephalosporins (total d)</td>
<td>3.5</td>
<td>4.1</td>
<td>0.88</td>
</tr>
<tr>
<td>Antibiotics (total d)</td>
<td>12.6</td>
<td>15.4</td>
<td>0.19</td>
</tr>
<tr>
<td>Postnatal steroids (total d)</td>
<td>0.4</td>
<td>1.2</td>
<td>0.07</td>
</tr>
<tr>
<td>Mean duration of stay in NICU (d)</td>
<td>42</td>
<td>45</td>
<td>0.99</td>
</tr>
<tr>
<td>Central venous catheter(s) positioned (d)</td>
<td>16.4</td>
<td>20.1</td>
<td>0.10</td>
</tr>
<tr>
<td><strong>Nutritional characteristics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time of initiation of oral feeding (DOL)</td>
<td>3.3</td>
<td>3.8</td>
<td>0.14</td>
</tr>
<tr>
<td>Time of achievement of full feeding (DOL)</td>
<td>12.7</td>
<td>14.3</td>
<td>0.25</td>
</tr>
<tr>
<td>Mean volume of feedings advancements daily (mL/d)</td>
<td>10.0</td>
<td>10.5</td>
<td>0.69</td>
</tr>
<tr>
<td>Proportions of infants fed with only formula</td>
<td>19%</td>
<td>17%</td>
<td>0.70</td>
</tr>
<tr>
<td>Daily average amounts of human fresh milk intake (mL/kg)</td>
<td>68.5</td>
<td>65.0</td>
<td>0.99</td>
</tr>
<tr>
<td>Total days of human fresh milk feeding</td>
<td>30</td>
<td>29</td>
<td>0.99</td>
</tr>
</tbody>
</table>

DOL, day of life; NICU, neonatal intensive care unit; SD, standard deviation; TPN, total parenteral nutrition.
Screened and assessed for eligibility (n = 247)

Excluded (n = 18)
- Not meeting inclusion criteria (n = 1)
- Refused to participate (n = 14)
- Other reasons (n = 3)

Allocated to intervention (n = 113)
- Received allocated intervention (n = 113)
- Did not receive allocated intervention (n = 0)

Lost to follow-up (n = 0)

Discontinued intervention (n = 1)
Give reasons: did not receive 5 doses of the study drug due to error

Allocated to CONTROLS (n = 116)
- Received placebo (n = 116)
- Did not receive placebo (n = 0)

Lost to follow-up (n = 0)

Discontinued intervention (n = 0)

Analyzed (n = 113)
- Excluded from analysis (n = 0)
- Give reasons: incomplete data: (n = 2)

Analyzed (n = 116)
- Excluded from analysis (n = 2)
- Give reasons: incomplete data: (n = 2)

Figure 1 Flowchart (August 2005).

Table 2 Main Results

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Lutein</th>
<th>Placebo</th>
<th>OR</th>
<th>95% CI</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary outcomes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Threshold ROP</td>
<td>7/113</td>
<td>12/116</td>
<td>0.60</td>
<td>0.24–1.46</td>
<td>0.18</td>
</tr>
<tr>
<td>NEC &gt; 2nd stage</td>
<td>2/113</td>
<td>6/116</td>
<td>0.34</td>
<td>0.07–1.66</td>
<td>0.15</td>
</tr>
<tr>
<td>BPD</td>
<td>5/113</td>
<td>12/116</td>
<td>0.43</td>
<td>0.15–1.17</td>
<td>0.07</td>
</tr>
<tr>
<td>Secondary outcomes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ROP all stages</td>
<td>23/113</td>
<td>27/116</td>
<td>0.87</td>
<td>0.53–1.43</td>
<td>0.35</td>
</tr>
<tr>
<td>Progression from ROP any stage to threshold ROP</td>
<td>7/23</td>
<td>12/27</td>
<td>0.68</td>
<td>0.32–1.44</td>
<td>0.23</td>
</tr>
<tr>
<td>Mortality (all-cause, prior to discharge)</td>
<td>3.8%</td>
<td>4.6%</td>
<td>0.72</td>
<td>0.22–1.59</td>
<td>0.89</td>
</tr>
<tr>
<td>Transfusions (mean ± SD)</td>
<td>3.1 ± 2</td>
<td>4.0 ± 3</td>
<td>0.76</td>
<td>0.20–1.49</td>
<td>0.78</td>
</tr>
<tr>
<td>Hyperbilirubinemia &gt; 14.0 mg/dL</td>
<td>6/113</td>
<td>7/116</td>
<td>0.85</td>
<td>0.59–1.70</td>
<td>0.48</td>
</tr>
<tr>
<td>Late-onset sepsis</td>
<td>17.5%</td>
<td>20.3%</td>
<td>0.83</td>
<td>0.42–1.67</td>
<td>0.88</td>
</tr>
<tr>
<td>Severe (grade 3–4) intraventricular hemorrhage</td>
<td>4.0%</td>
<td>4.8%</td>
<td>0.85</td>
<td>0.36–1.88</td>
<td>0.90</td>
</tr>
<tr>
<td>Threshold ROP and/or BPD and/or NEC &gt; 2nd stage</td>
<td>13/113</td>
<td>23/116</td>
<td>0.580</td>
<td>0.30–1.08</td>
<td>0.08</td>
</tr>
</tbody>
</table>

BPD, bronchopulmonary dysplasia; CI, confidence interval; NEC, necrotizing enterocolitis; OR, odds ratio; ROP, retinopathy of prematurity; SD, standard deviation.
Our aim was to establish whether supplementation of lutein + zeaxanthin is safe and helps prevent ROP, NEC, and BPD in VLBW infants. Unfortunately, the results are inconclusive.

ROP, NEC, and BPD manifested a decreasing trend in the infants who received lutein + zeaxanthin (see Table 2). Supplemented infants had a 40% reduction in threshold ROP, a 52% reduction in BPD, a 73% reduction in NEC, and a 35% reduction in the rate of progression from stage I or II ROP to threshold ROP. Although these decreases are not statistically significant, they appear relevant and are consistent among the different outcomes.

Of note, no pharmacodynamics/pharmacokinetics data are available in literature to suggest optimal dosing, and we identified the dosage to be used in this study on the basis of the GRAS declaration-related documents, which do not specifically refer to preterm infants. Therefore, we cannot exclude that dosing should be increased to achieve a positive effect in preterm infants whose risk for outcomes related to oxidative stress is high.

We used the same dosage of lutein + zeaxanthin supplements for all patients irrespective of the degree of prematurity and of type of feeding (maternal, donor, formula milk, or mixed). It would be interesting to understand whether these variables should affect optimal dosage.

It is also possible that, although we enrolled over 200 infants, the sample size was still too small. This limitation is inherent to the fact that this study to our knowledge is the first of its kind.

The rationale for supplementing carotenoids in premature infants is based on several points.

In the neonatal period, fresh, not-processed human milk is the main dietary source of lutein and zeaxanthin, and breast-fed infants have higher mean serum lutein concentrations than infants who consume formula or unfortified with lutein. It has been calculated that times more lutein is needed in infant formula than in human milk to achieve similar serum lutein concentrations among breast-fed and formula-fed infants.

Carotenoids in human milk are a main player in an antioxidative network of bioactive, human milk substances that exert protective functions against oxidative stress. Damage related to oxidative stress occurring in different peripheral tissues is an etiologic moment that is common to several severe outcomes of prematurity such as ROP, NEC, and BPD. Noteworthy, breast-feeding has been associated with lower incidence rates of all of these outcomes.

Lutein and all carotenoids provide relevant in vivo antioxidative and anti-reactive oxygen species) activities through inhibition of membrane lipids’ peroxidation and scavenger radical-trapping activity and via a quenching effect toward singlet and triplet oxygen. In addition, lutein and zeaxanthin ensure protection against both light-induced and metabolic oxidative damage in the retina and in other developing tissues.

In a recent pilot RCT in healthy newborns, lutein administration proved effective in increasing the levels of biological antioxidant potential by decreasing the total hydroperoxides as markers of oxidative stress. Plasma β-carotene concentrations have indeed been found to be lower in BPD infants, which may result in a reduction of their antioxidant protection. Once more, in our study, the effect of lutein + zeaxanthin on prevention of BPD appears relevant, although not statistically significant.

Clinical signs related to oxidative stress may take years and sometimes decades to become manifest. One limitation of our study is that the outcomes were assessed at discharge or at term-corrected gestational age, whichever came first. It might be worthwhile extending the evaluation of possible effects on health of early carotenoid supplementation to childhood and adulthood. In adult humans, increased dietary intake of lutein protects against the development of early atherosclerosis.

In this study, lutein and zeaxanthin supplementation in VLBW infants appeared well tolerated and not associated with any adverse effect or putative toxicity. This is consistent with similar safety findings in adults, where in some studies much higher concentrations lutein/zeaxanthin were in fact used.

In conclusion, this RCT does not clarify whether supplementation of lutein and zeaxanthin since birth is associated with decreased incidences of several multifactorial prematurity outcomes related to oxidative stress occurring in the early ages of life. The nonsignificant decreasing trends for ROP, NEC, and BPD disclosed by our study should be confirmed in further studies with adequately powered cohorts.

Acknowledgments

Table 3 Liver Function Tests Results

<table>
<thead>
<tr>
<th></th>
<th>Group A: Lutein (n = 113)</th>
<th>Group B: Placebo (n = 116)</th>
<th>p Value Group A versus Group B</th>
</tr>
</thead>
<tbody>
<tr>
<td>AST all infants</td>
<td>21.3 (±11)</td>
<td>24.3 (±10)</td>
<td>0.80</td>
</tr>
<tr>
<td>ALT all infants</td>
<td>18.5 (±13)</td>
<td>19.9 (±12)</td>
<td>0.65</td>
</tr>
<tr>
<td>γGT all infants</td>
<td>152 (±78)</td>
<td>119 (±65)</td>
<td>0.08</td>
</tr>
<tr>
<td>Direct bilirubin all infants</td>
<td>2.2 (±1.6)</td>
<td>2.3 (±1.8)</td>
<td>0.78</td>
</tr>
</tbody>
</table>

All values are in mg/dL. AST, aspartate aminotransferase; ALT, alanine aminotransferase; γGT, gamma-glutamil transferase.
In addition to the authors, the task force includes the following persons: Amelia Di Comite, Alessandro Borghesi, Lidia Decembrino, Chryssoula Tzialla (NICU, IRCCS S. Matteo, Pavia); Giovanni Agriesti, Caterina Franco, Stefano Rizzollo, Riccardo Arisio, Giovanna Comirato, Chiara Giovannozzi (NICU, S. Anna Hospital, Torino); Domenico Cipolla (NICU, University of Palermo); Fabio Natale (NICU, La Sapienza University, Roma); Gennaro Vetranò (NICU, Fatebenefratelli Hospital, Benevento); Elisabetta Tridapalli, Maria Grazia Capretti (NICU, University of Bologna); PierMichele Paolillo, Simonetta Picone (Neonatology Policlinico Casilino, Roma); Elio Castagnola (Infectious Disease Unit, Gaslini Hospital, Genova); Francesco Risso (Neonatology and NICU, Gaslini Hospital, Genova).

Note
Some data from this study were presented in abstract form as preliminary data at the First International Conference on Clinical Neonatology held in Torino, Italy (November 12 to 14, 2009), and at the 2011 SPR Conference in Denver, Colorado (May 1 to 4, 2011).

Conflict of Interest
The study was partially supported by unrestricted grant provided by SOOFT Italia.

References